Founded and led by Dr. John Reveille, the UTHealth Houston Spondyloarthritis program, is committed to providing state-of-the-art care and conducting groundbreaking research for those affected by spondyloarthritis since 1999. Spondyloarthritis encompasses a heterogeneous group of diseases, including ankylosing spondylitis, psoriatic arthritis, inflammatory-bowel-related arthritis, recurrent uveitis, non-radiographic axial spondyloarthritis, and undifferentiated spondyloarthritis. Our physicians are faculty members of the McGovern Medical School and are board-certified in Rheumatology. At the core of our program have been the hundreds of dedicated patients who have contributed to our understanding of these diseases. We are involved in one of the largest existing cohorts of ankylosing spondylitis (AS) patients world-wide, with thousands of participants that have helped define the understanding of the pathogenesis, treatment, and outcomes of this disease. In a true comprehensive, patient-oriented approach, we conduct spondyloarthritis research ranging from: molecular profiling of disease manifestations, understanding the patient experience through study of patient-reported outcomes, and capturing the disease burden through our longitudinal cohort and conducting both industry-sponsored and investigator-initiated clinical trials of treatments of spondyloarthritis.